Myriad Genetics (MYGN) Short-Term Debt issuances (2018 - 2025)
Historic Short-Term Debt issuances for Myriad Genetics (MYGN) over the last 4 years, with Q1 2025 value amounting to $40.0 million.
- Myriad Genetics' Short-Term Debt issuances fell 3333.33% to $40.0 million in Q1 2025 from the same period last year, while for Sep 2025 it was $60.0 million, marking a year-over-year decrease of 5714.29%. This contributed to the annual value of $120.0 million for FY2024, which is 5000.0% up from last year.
- Myriad Genetics' Short-Term Debt issuances amounted to $40.0 million in Q1 2025, which was down 3333.33% from $20.0 million recorded in Q4 2024.
- In the past 5 years, Myriad Genetics' Short-Term Debt issuances ranged from a high of $60.0 million in Q1 2024 and a low of $20.0 million during Q2 2024
- In the last 3 years, Myriad Genetics' Short-Term Debt issuances had a median value of $40.0 million in 2023 and averaged $34.3 million.
- In the last 5 years, Myriad Genetics' Short-Term Debt issuances plummeted by 5000.0% in 2024 and then tumbled by 3333.33% in 2025.
- Over the past 3 years, Myriad Genetics' Short-Term Debt issuances (Quarter) stood at $40.0 million in 2023, then tumbled by 50.0% to $20.0 million in 2024, then surged by 100.0% to $40.0 million in 2025.
- Its last three reported values are $40.0 million in Q1 2025, $20.0 million for Q4 2024, and $20.0 million during Q3 2024.